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Osteodystrophy in the millennium. Despite three decades of be insufficient control of hyperphosphatemia. As one
intensive research on the derangements of calcium phosphate case in point, even in Japan, where the average weight
metabolism of renal failure, several unresolved issues are still of the patients is 52 kg and the average duration ofwith us at the turn of the millennium: poor control of hyper-
hemodialysis 3 3 4.2 6 0.5 hr [1], predialytic serumphosphatemia, relative inefficacy of active vitamin D to prevent
progressive parathyroid hyperplasia, and persistence of bone phosphate is 1.86 6 0.54 mm. The average predialytic
disease despite lowering of parathyroid hormone (PTH) and serum phosphate concentration in 227 patients treated
administration of active vitamin D. Although predictions are in our center is 1.78 6 0.52 mm, despite an average useproblematic, it is not unreasonable to hope that, barring unfore-
of calcium carbonate of 1.4 6 1.8 g/day and (with 37% ofseen side effects, calcimimetics will prove to be valuable for
the patients taking, in addition, low doses of aluminum-suppressing or even preventing hyperparathyroidism, thus po-
tentially replacing, at least in part, active vitamin D. There is containing phosphate binders). Why is it so difficult to
also reason to hope that more effective phosphate binders with normalize serum phosphate? The main issue is the com-
fewer side effects will become available and that controlled
plex kinetics of elimination of phosphate. Phosphate isstudies will provide a rationale for the administration of estro-
trapped in deep compartments, and the transfer rategens to dialyzed women. As regards understanding the patho-
logical mechanisms, one can anticipate that the disturbances constant for phosphate efflux from the intracellular to
leading to autonomous growth of parathyroid cells will be the extracellular compartment is low relative to the rate
elucidated and the signals involved in osteoclast/osteoblast dif- of removal of phosphate during high efficiency dialysisferentiation pathways and osteoclast/osteoblast coupling will
sessions. Most of the phosphate is removed in the firstbe clarified, with obvious impact on patient management.
hour of dialysis and despite unchanged dialysance for
phosphate, only a relatively small amount of phosphate
The literature is replete with warnings against making is subsequently eliminated because serum phosphate
predictions about the future. Unable to resist the insis- concentrations are low. But we also believe that in many
tence of the organizers, we had to give in and commit instances hyperphosphatemia is simply a surrogate
ourselves to make predictions, but we find consolation marker for under-dialysis. Against this background, it is
in the consideration that either we are right (in which of interest that long slow dialysis sessions provide more
case future generations will praise us for our clairvoy- effective removal of phosphate to the point that one may
ance) or we are wrong (in which case our predictions even have to add phosphate to the dialysate fluid [2].
will be painlessly and thoroughly forgotten anyway). Apart from the well-known effects of phosphate in the
This is an interesting time to take one step back and genesis of hyperparathyroidism [3], a high serum phos-
to consider where we might go from here. A number of phate concentration is also a predictor of poor survival
remarkable developments have recently occurred, both on dialysis [4] (abstract; J Am Soc Nephrol 9:217A, 1998).
in regard to strategies of patient management and in This may in part be due to calcification of coronary
regard to basic understanding of molecular mechanisms. plaques [5], but in recent experimental studies hyper-
It is useful first to take stock of what problems persist phosphatemia was also associated with cardiac microcir-
in 1999 and then speculate about potential future direc-
culatory abnormalities [6].
tions.
The problem of phosphate control is compounded by
the fact that none of the existing phosphate binders is
PHOSPHATE CONTROL truly satisfactory. Aluminum-containing phosphate bind-
ers are relatively contraindicated because of aluminumThe main problem, perhaps the major problem in the
toxicity. Calcium-containing phosphate binders predis-management of divalent ion metabolism, continues to
pose to hypercalcemia [7]. This has prompted the devel-
opment of novel phosphate binding compounds suchKey words: renal osteodystrophy, vitamin D, PTH, adynamic bone
disease, estrogens, hyperphosphatemia. as polyallylamine hydrochloride (Sevelamert)—which
is effective, but with which it is difficult to consistently 1999 by the International Society of Nephrology
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achieve normophosphatemia [8]—lanthanum carbonate, once active vitamin D was administered, the structure
and the dynamics of bone would be normalized. A numberfor which no published information is available, and
phosphate binders on the basis of trivalent iron [9, 10], of investigators [24, 25] noted that on average bone turn-
over in dialyzed uremic patients was normal only whenwhich appear promising and are relatively cheap. Be-
cause of the importance of phosphate in triggering hyper- the measured immune reaction 1,84 iPTH concentrations
were 2- to 3-fold above the normal range. The explana-parathyroidism [3, 11, 12] and predisposing to cardiovas-
cular events [4, 6], efforts to modify dialysis strategies tion for this observation is not unambiguous. The assay
apparently measures bio-inactive fragments [26], so that[2] and to develop new phosphate binders are of prime
importance. in these studies measured 1,84 iPTH concentrations may
have been spuriously elevated. On the other hand, in
many organs including bone tissue, expression of PTH/RELATIVE INEFFICACY OF ACTIVE VITAMIN
PTH-related polypeptide receptor is diminished in renalD TO CONTROL PARATHYROID GROWTH
failure [27, 28], so that it is conceivable that there is an
There is no doubt that active vitamin D preparations element of hyporesponsiveness to PTH at the receptor
acutely suppress parathyroid hormone (PTH) secretion. level and abnormalities on the postreceptor level are
Nevertheless, although controlled evidence is not avail- also certainly not excluded. Finally, in many hormonal
able, it appears that they cannot completely prevent de- systems it is not only the concentration of the hormone,
velopment and progression of parathyroid hyperplasia. but also the temporal pattern of hormone concentra-
In several studies, the duration of dialysis treatment was tions, that determines end-organ response. Pulsatile se-
a potent predictor of parathyroidectomy [13]. According cretion of luteinizing hormone (LH)–releasing hormone
to the EDTA registry [14], up to 10–15% of chronic (RH) provokes LH secretion by the hypophysis, while
dialysis patients ultimately require parathyroidectomy. continuous administration of LH-RH blocks LH release
In our center, 16 of 95 patients dialyzed for more than and is used for medical ablation of the hormone. In this
10 years required parathyroidectomy. context it is of interest that the pattern of pulsatile PTH
Why is control of parathyroid growth unsatisfactory? secretion is strikingly abnormal in uremic patients [29].
There may be several causes. One important point is Preliminary studies in conjunction with the Department
of course persisting hyperphosphatemia in view of the of Pediatrics, Heidelberg, show that the bone cell re-
potent stimulatory effect of phosphate on parathyroid sponse to PTH depends on the temporal pattern of expo-
cell proliferation [3, 11, 12]. Another important point is sure to PTH (unpublished data).
the fact that parathyroid hyperplasia, at least advanced It is uncertain whether abnormalities in the calcium
(nodular) hyperplasia, is largely irreversible. It is true regulatory hormones fully explain adynamic bone dis-
that in animal experiments, hyperplastic glands of uremic
ease in patients with low PTH. One has certainly also to
rats can regress [15], but this may not be an adequate
consider alternative possibilities. Recently we compared
model for what is seen in chronically uremic patients,
subtotally nephrectomized, parathyroidectomized ratsi.e., nodular parathyroid hyperplasia with monoclonal
that received either solvent or nonhypercalcemic dosesgrowth [16], loss of heterozygosity with loss of putative
of aminoterminal rat PTH and 1,25(OH)2D3 [30]. Bonetumor suppressor genes [17] and reduced expression of
histology was not restored to normal by administrationthe vitamin D receptor [18] and calcium receptor [19],
of the calcium-regulatory hormones. Such unrespon-respectively. It appears plausible [20], but is currently
siveness might be explained by the artefactual non-pulsa-unproven, that prophylaxis, i.e., normalization of phos-
tile mode of administration or by an element of resistancephatemia [21] and administration of low doses of active
to PTH or 1,25(OH)2D3, as discussed above, but recentvitamin D [22], may interfere with the development of
insights into the regulation of osteoclast and osteoblastparathyroid hyperplasia. One must also consider the al-
developmental pathways suggest interesting alternativeternative possibility: that signals other than hyperphos-
possibilities [31, 32]. In osteoclast and osteoblast differ-phatemia and diminished active vitamin D are involved
entiation, the calcium regulatory hormones influencein the genesis of parathyroid hyperplasia. In this context,
only late steps, while colony-stimulating factors (mCSF,recent observations on the prevention of parathyroid
gmCSF) or interleukins (IL-6, IL-11) affect early steps.hyperplasia by calcimimetic agents [23] are of consider-
In addition, a circulating molecule of the tumor necrosisable interest. At present, the potential role of these
factor (TNF) receptor family, osteoprotegerin, is pro-agents in the prevention and control of parathyroid hy-
duced in the kidney. It inhibits late stages of osteoclastperplasia cannot be properly assessed.
development, so that one would expect increased osteo-
clastogenesis if this factor is not present. This was not
PERSISTING BONE ABNORMALITIES observed in our study [30]. But circulating substances
may also interfere with osteoblast function. As a case inIn the distant past it had been hoped that once PTH
concentrations were kept within the normal range and point, Andress [33] documented the presence of a low
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molecular weight inhibitor of osteoblast mitogenesis in still murky and the results reported are conflicting [40].
Nevertheless, this field holds great promise and mightthe plasma of uremic patients. There are further possibil-
ities to consider. In principle, in the genesis of the low open new perspectives to better define patients at high
risk of secondary hyperparathyroidism or bone loss.bone turnover (adynamic bone disease), either agonists
of bone formation could be suppressed or promotors of
bone formation be deficient. Known suppressors include
WHAT DO WE EXPECT IN THE
IL-11 [34] and IL-4 [35], particularly osteogenic protein-1
NEW MILLENNIUM?
or bone morphogenetic protein 7, which is produced by
Management of renal bone diseasenormal renal tubular cells (abstract; J Am Soc Nephrol
As far as patient management is concerned, we expect4:700, 1993) and is presumably reduced or absent in
that calcimimetics will become a major tool in the man-renal failure. Because of the considerable therapeutic
agement of the uremic patient, both for the preventionpotential for the treatment of osteoporosis, many phar-
and for the treatment of secondary hyperparathyoidism.maceutical companies have launched considerable ef-
The available evidence [41–44] is very encouraging andforts to define these factors. Osteoprotegerin and osteo-
it is hoped that long-term safety studies do not revealprotegerin ligand (formerly called TRACE) have been
major extraparathyroidal side effects, a concern becauseisolated and sequenced. Furthermore, factors essential
of the nearly ubiquitous expression of the calcium sensor.for osteoblast differentiation, e.g., core-binding factor
In this respect, the absence of such effects in a patientalpha 1 (CBFA-1) (heterozygous loss of which causes
treated for 2 years is quite encouraging [45]. It is difficultcleidocranial dysplasia in humans) have also been identi-
to predict the relative roles that calcimimetics and activefied [36]. The physiology of these factors in renal failure
vitamin D will have in the future; these roles will haverequires further study, but this whole field potentially
to be worked out in controlled trials. It is conceivableopens exciting new perspectives for understanding ady-
that active vitamin D may be necessary for maintainingnamic bone disease. Even though we have managed to
active calcium transport in the intestine or for exertinglower PTH and administer active vitamin D, new distur-
specific effects on the numerous target tissues which ex-bances are now observed that cannot be fully explained
press vitamin D receptors, for instance muscle, vascula-by abnormalities of calcium regulatory hormones.
ture, immune cells, etc.
Secondly, we expect that we shall see more effective
ESTROGENS AND BONE phosphate binders with fewer side effects.
Estrogens affect the parathyroid gland as well as bone Finally, we presume that clinical nephrologists will
[37]. Because of the obvious importance in the genesis recognize that estrogens are potent agonists on bone and
will use these compounds more liberally.of postmenopausal osteoporosis, this field has been in-
tensely investigated, but so far this has had disappoint-
Pathophysiological mechanismsingly little impact on the management of female patients
Clinical common sense helps to predict what is plausi-on dialysis. Estrogens have remained a Cinderella in the
ble and what is not with respect to management of renaltherapeutic repertoire of nephrologists. Only approxi-
bone disease. When one comes to basic research, how-mately 5% of amenorrheic patients had received estrogens
ever, one is on more uncertain ground. Presumably, thein the modification of diet in renal disease trial. Apart from
fundamental challenge will be to clarify why control offew preliminary studies [38] that point to preservation or
parathyroid growth is disturbed, i.e., to explain the occur-increase of bone mineral content after administration of
rence of monoclonal growth, loss of heterozygosity withlow dose estrogens to dialyzed amenorrheic women, no
hypothetical loss of tumor suppressor genes, and de-information is available. Recently, estrogen analogs—
differentiation of parathyroid cells, so that vitamin De.g., raloxifen [39]—have become available that selec-
receptor and calcium sensor molecules are no longertively affect bone without causing endometrial hyperpla-
expressed normally. Recent studies showed alterationssia and endometrial cancer. There is an urgent need to
of genomic DNA in blood cells of dialyzed patients. Oneclarify the role of estrogens in the genesis, and their poten-
could therefore speculate that it is in the parathyroidtial in the treatment, of bony abnormalities in uremia.
gland as well as in the remnant kidney (in other words
tissues actively proliferating in uremia, but normally ex-
GENETICS AND BONE DISEASE hibiting low cell turnover) that such genomic lesions
Genes, or more precisely genetic polymorphisms, ap- lead more readily to abnormal growth, i.e., monoclonal
pear to determine both bone mass and susceptibility of parathyroid nodules and renal cell carcinoma, respec-
the parathyroid to stimulation. Some of the genes that tively. It is still puzzling why one mostly sees autono-
have been implied are the vitamin D receptor, calcium mous, but not malignant growth, in the parathyroids of
uremic patients.sensing receptor, isocollagens, etc. Currently this field is
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phatemia in hemodialysis patients. Am J Kidney Dis 33:694–701,There are also glaring deficits in our understanding
1999
of the signals of the osteoclast/osteoblast differentiation 9. Hergesell O, Ritz E: Stabilized polynuclear iron hydroxide is an
efficient oral phosphate binder in uraemic patients. Nephrol Dialpathways and similar defects in understanding how the
Transplant 14:863–867, 1999balance between bone resorption and formation is main-
10. Hsu CH, Patel SR, Young EW: New phosphate binding agents:
tained, i.e., the coupling between the two processes. ferric compounds. J Am Soc Nephrol 10:1274–1280, 1999
11. Almaden Y, Hernandez A, Torregrosa V, Canalejo A, SabateKnowledge of these mechanisms is crucial for the under-
L, Fernandez Cruz L, Campistol JM, Torres A, Rodriguezstanding of adynamic bone disease and bone loss, respec-
M: High phosphate level directly stimulates parathyroid hormone
tively. Because of the enormous potential market that secretion and synthesis by human parathyroid tissue in vitro. J Am
Soc Nephrol 9:1845–1852, 1998treatment of osteoporosis offers, these issues are cur-
12. Miyamoto K, Tatsumi S, Morita K, Takeda E: Does the parathy-rently hotly investigated by the pharmaceutical industry,
roid ‘see’ phosphate? Nephrol Dial Transplant 13:2727–2729, 1998
as evidenced by the recent cloning of osteoprotegerin 13. Mizumoto D, Watanabe Y, Fukuzawa Y, Yuzawa Y, Yamazaki
C: Identification of risk factors on secondary hyperparathyroidismand the osteoprotegerin ligand in pharmaceutical labora-
undergoing long-term haemodialysis with vitamin D3. Nephroltories.
Dial Transplant 9:1751–1758, 1994
The above listing may to some extent reflect personal 14. Fassbinder W, Brunner FP, Brynger H, Ehrich JH, Geerlings
W, Raine AE, Rizzoni G, Selwood NH, Tufveson G, Wing AJ:preferences and there is undoubtedly room for many
Combined report on regular dialysis and transplantation in Europe,other considerations. We are skeptical whether one area,
XX, 1989. Nephrol Dial Transplant 6 (Suppl. 1):5–35, 1991
namely vitamin D analogs, holds great potential. Al- 15. Lewin E, Wang W, Olgaard K: Reversibility of experimental
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16. Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Drueketive, one sorely misses clinical head-on comparisons of
TB: Monoclonality of parathyroid tumors in chronic renal failure
efficacy and safety with calcitriol or 1-alpha. and in primary parathyroid hyperplasia. J Clin Invest 95:2047–2053,
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17. Chudek J, Ritz E, Kovacs G: Genetic abnormalities in parathyroidinsights hopefully are closer to the truth than the famous
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